source
- Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitorWindward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
- Bristol Myers appoints Cristian Massacesi as head of R&D as Robert Plenge exitsBristol Myers Squibb announced a reorganization of its research and development organization, merging the research and development units under a single leader. Cristian Massacesi, currently chief…